Gossamer Bio Inc. (GOSS) Misses Q3 EPS by 2c; Reports Cash and Cash Equivalents of $366.0M

Gossamer Bio Inc. (NASDAQ: GOSS) reported Q3 EPS of ($0.80), $0.02 worse than the analyst estimate of ($0.78).

For earnings history and earnings-related data on Gossamer Bio Inc. (GOSS) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth